Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Formation of the Platelet Plug

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...

Structure and Function of Platelets

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Severe Optic Neuroretinitis and Vitreous Hemorrhage in Pediatric Cat-Scratch Disease: A Case With Irreversible Visual Impairment.

The American journal of case reports·2026

Same author

Correction: Investigation of optimal settings for deviceless respiratory synchronization in PET/CT examinations: effects of different reconstructions on image quality.

Radiological physics and technology·2025

Same author

Investigation of optimal settings for deviceless respiratory synchronization in PET/CT examinations: effects of different reconstructions on image quality.

Radiological physics and technology·2025

Same author

Preparation of Comb-Shaped Polyether with PDMS and PEG Side Chains and Its Application in Polymer Electrolytes.

Molecules (Basel, Switzerland)·2025

Same author

A Disease Progression Predictor by Quantitative Assessment of the Hepatic Accumulation on Postablative Iodine-131 Whole-Body Image in Differentiated Thyroid Cancer.

Molecular imaging and radionuclide therapy·2025

Same author

Aneurysms Associated with Hyperplastic Anterior Choroidal Arteries: Three Cases with Literature Review.

Journal of neuroendovascular therapy·2025

Search research articles

Related Experiment Video

Updated: Jul 2, 2026

Routine Screening Method for Microparticles in Platelet Transfusions

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

[The effect of operating time of PMX-DHP on decrease of platelets].

Kazushige Ooishi¹, Takashi Etou, Satoko Koga

¹Department of Anesthesiology and Intensive Care Medicine, Beppu Medical Center, Ooita 874-0011.

Masui. the Japanese Journal of Anesthesiology

|August 20, 2008

Summary

Long-term use of polymyxin B-hemoperfusion (PMX-DHP) appears safe for severe septic shock, as platelet decrease remains consistent regardless of treatment duration. This finding supports PMX-DHP

More Related Videos

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

Related Experiment Videos

Last Updated: Jul 2, 2026

Routine Screening Method for Microparticles in Platelet Transfusions

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

Area of Science:

Critical Care Medicine
Nephrology
Immunology

Background:

Long-term polymyxin B-hemoperfusion (PMX-DHP) is increasingly recognized for its benefits in severe septic shock.
A known complication of PMX-DHP is a decrease in platelet count, necessitating further investigation into its relationship with treatment duration.

Purpose of the Study:

To investigate the impact of PMX-DHP operating time on the reduction of platelet counts in patients with severe septic shock.

Main Methods:

A retrospective analysis was conducted on 49 patients with severe septic shock undergoing PMX-DHP.
Patients were categorized into three groups based on PMX-DHP operating time: Short (S, <4 hours), Intermediate (I, 4-12 hours), and Long (L, 12-24 hours).
The rate of platelet decrease was compared across these subgroups.

Main Results:

The mean platelet decrease rates were 16.7% (S group), 25.5% (I group), and 23.7% (L group).
No statistically significant differences in platelet decrease rates were observed between the short, intermediate, and long operating time groups.

Conclusions:

Platelet reduction during PMX-DHP was approximately 20%, consistent with previous reports and independent of treatment duration.
PMX-DHP, even with extended use up to 24 hours, is considered practically safe concerning platelet levels in severe septic shock management.